Donald G. Musson

2.3k total citations
78 papers, 1.8k citations indexed

About

Donald G. Musson is a scholar working on Pharmacology, Molecular Biology and Spectroscopy. According to data from OpenAlex, Donald G. Musson has authored 78 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pharmacology, 23 papers in Molecular Biology and 22 papers in Spectroscopy. Recurrent topics in Donald G. Musson's work include Antibiotics Pharmacokinetics and Efficacy (27 papers), Analytical Chemistry and Chromatography (21 papers) and Analytical Methods in Pharmaceuticals (16 papers). Donald G. Musson is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (27 papers), Analytical Chemistry and Chromatography (21 papers) and Analytical Methods in Pharmaceuticals (16 papers). Donald G. Musson collaborates with scholars based in United States, Belgium and Japan. Donald G. Musson's co-authors include Alison L. Fisher, Wei Zeng, Lihong Du, John Rogers, Anup Majumdar, K. C. Yeh, W.F. Bayne, Eric Woolf, Yang Xu and Kenneth C. Lasseter and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Analytical Biochemistry.

In The Last Decade

Donald G. Musson

77 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donald G. Musson United States 27 553 430 324 274 227 78 1.8k
Francis L. S. Tse Japan 28 496 0.9× 721 1.7× 239 0.7× 486 1.8× 116 0.5× 110 2.7k
Gordon McKay Canada 17 486 0.9× 436 1.0× 266 0.8× 266 1.0× 123 0.5× 23 2.1k
J P Tillement France 25 247 0.4× 657 1.5× 69 0.2× 142 0.5× 163 0.7× 100 1.8k
G.J. Krol United States 18 398 0.7× 190 0.4× 148 0.5× 163 0.6× 44 0.2× 37 1.1k
L Balant Switzerland 26 370 0.7× 395 0.9× 159 0.5× 201 0.7× 110 0.5× 85 1.9k
Emi Nakashima Japan 24 558 1.0× 619 1.4× 65 0.2× 134 0.5× 85 0.4× 98 2.4k
Soo Kyung Bae South Korea 30 357 0.6× 1.1k 2.5× 210 0.6× 157 0.6× 179 0.8× 147 2.9k
A Marzo Italy 21 249 0.5× 291 0.7× 177 0.5× 219 0.8× 115 0.5× 122 1.4k
P.J. De Schepper Belgium 20 682 1.2× 682 1.6× 92 0.3× 51 0.2× 325 1.4× 53 2.0k
Atsushi Kurihara Japan 29 766 1.4× 686 1.6× 143 0.4× 67 0.2× 180 0.8× 88 3.7k

Countries citing papers authored by Donald G. Musson

Since Specialization
Citations

This map shows the geographic impact of Donald G. Musson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald G. Musson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald G. Musson more than expected).

Fields of papers citing papers by Donald G. Musson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald G. Musson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald G. Musson. The network helps show where Donald G. Musson may publish in the future.

Co-authorship network of co-authors of Donald G. Musson

This figure shows the co-authorship network connecting the top 25 collaborators of Donald G. Musson. A scholar is included among the top collaborators of Donald G. Musson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald G. Musson. Donald G. Musson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Vuillemenot, Brian R., Derek Kennedy, Jonathan D. Cooper, et al.. (2014). Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Molecular Genetics and Metabolism. 114(2). 281–293. 49 indexed citations
3.
4.
5.
Yang, Amy Y., Li Sun, Donald G. Musson, & Jamie J. Zhao. (2005). Determination of M+4 stable isotope labeled cortisone and cortisol in human plasma by µElution solid‐phase extraction and liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 20(2). 233–240. 11 indexed citations
6.
Xu, Yang, Lihong Du, Mark J. Rose, et al.. (2005). Concerns in the development of an assay for determination of a highly conjugated adsorption-prone compound in human urine. Journal of Chromatography B. 818(2). 241–248. 31 indexed citations
7.
Wong, B K, Xin Xu, Sean Yu, et al.. (2004). Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica. 34(4). 379–389. 19 indexed citations
8.
Zeng, Wei, et al.. (2004). High-throughput liquid chromatography for drug analysis in biological fluids: investigation of extraction column life. Journal of Chromatography B. 806(2). 177–183. 27 indexed citations
9.
Wang, Amy Q., Wei Zeng, Donald G. Musson, John Rogers, & Alison L. Fisher. (2002). A rapid and sensitive liquid chromatography/negative ion tandem mass spectrometry method for the determination of an indolocarbazole in human plasma using internal standard (IS) 96‐well diatomaceous earth plates for solid‐liquid extraction. Rapid Communications in Mass Spectrometry. 16(10). 975–981. 29 indexed citations
10.
Zhang, Jin, et al.. (2002). Direct-injection HPLC assay for the determination of a new carbapenem antibiotic in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 27(5). 755–770. 2 indexed citations
11.
Goldberg, Michael R., et al.. (1999). Lack of Pharmacokinetic and Pharmacodynamic Interaction between Rizatriptan and Paroxetine. The Journal of Clinical Pharmacology. 39(2). 192–199. 19 indexed citations
12.
Demetriades, J.L., et al.. (1997). Stereoselective determination of R-(+)- and S-(−)-remoxipride, a dopamine D2-receptor antagonist, in human plasma by chiral high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 700(1-2). 165–173. 5 indexed citations
13.
Musson, Donald G., et al.. (1992). An In Vitro Comparison of the Permeability of Prednisolone, Prednisolone Sodium Phosphate, and Prednisolone Acetate Across the NZW Rabbit Cornea. Journal of Ocular Pharmacology and Therapeutics. 8(2). 139–150. 13 indexed citations
14.
Musson, Donald G., et al.. (1991). Comparative Corneal Penetration of Prednisolone Sodium Phosphate and Prednisolone Acetate in NZW Rabbits. Journal of Ocular Pharmacology and Therapeutics. 7(2). 175–182. 12 indexed citations
15.
Yeh, K. C., et al.. (1989). Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.. PubMed. 39(11 Suppl 2). 25–38. 135 indexed citations
16.
17.
Musson, Donald G., et al.. (1986). Unexpected adduct ion formation under chemical ionization conditions. Journal of Mass Spectrometry. 13(6). 287–291. 1 indexed citations
18.
Musson, Donald G., et al.. (1984). Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability. Journal of Chromatography B Biomedical Sciences and Applications. 310(1). 71–84. 53 indexed citations
19.
Musson, Donald G., et al.. (1980). Synthetic and preliminary hemodynamic and whole animal toxicity studies on (R,S)-, (R)-, and (S)-2-methyl-3-(2,4,5-trihydroxyphenyl)alanine. Journal of Medicinal Chemistry. 23(12). 1318–1323. 11 indexed citations
20.
Bannister, S J, et al.. (1979). High-performance liquid chromatographic analysis of emetine after oxedative activation to a fluorescent product. Journal of Chromatography A. 176(3). 381–390. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francis L. S. Tse Breakdown of academic impact, for papers by Gordon McKay Breakdown of academic impact, for papers by J P Tillement Breakdown of academic impact, for papers by G.J. Krol Breakdown of academic impact, for papers by L Balant Breakdown of academic impact, for papers by Emi Nakashima Breakdown of academic impact, for papers by Soo Kyung Bae Breakdown of academic impact, for papers by A Marzo Breakdown of academic impact, for papers by P.J. De Schepper Breakdown of academic impact, for papers by Atsushi Kurihara
Rankless by CCL
2026